Masahiro Suzuki1, Takashi Matsuzuka1, Satoshi Saijo1, Miki Takahara2, Yasuaki Harabuchi2, Tsuyoshi Okuni3, Tetsuo Himi3, Tomohiko Kakizaki4, Satoshi Fukuda4, Kazuyuki Yamada5, Tatsumi Nagahashi5, Takahisa Abe6, Hideichi Shinkawa6, Katsunori Katagiri7, Hiroaki Sato7, Naoko Fukui8, Kazuo Ishikawa8, Takahiro Suzuki9, Toshimitsu Kobayashi9, Daisuke Saito10, Shigeru Saijo10, Masaru Tateda11, Sho Hashimoto11, Akihiro Ishida12, Seiji Kakehata12, Osamu Suzuki13, Yuko Hashimoto13, Koichi Omori1. 1. a Department of Otolaryngology , Fukushima Medical University School of Medicine , Fukushima , Japan. 2. b Department of Otolaryngology-Head , Neck Surgery, Asahikawa Medical University , Hokkaidou , Japan. 3. c Department of Otolaryngology , Sapporo Medical University School of Medicine , Hokkaidou , Japan. 4. d Department of Otolaryngology-Head and Neck Surgery , Hokkaido University Graduate School of Medicine , Hokkaidou , Japan. 5. e Department of Otolaryngology, Head and Neck Surgery , National Hospital Organization Hokkaido Cancer Center , Hokkaidou , Japan. 6. f Department of Otorhinolaryngology , Hirosaki University Graduate School of Medicine , Hokkaidou , Japan. 7. g Department of Otolaryngology , Iwate Medical University , Morioka-shi , Japan. 8. h Department of Otorhinolaryngology and Head and Neck Surgery , Akita University Graduate School of Medicine , Akita-shi , Japan. 9. i Department of Otolaryngology, Head and Neck Surgery , Tohoku University School of Medicine , Sendai-shi , Japan. 10. j Department of Head and Neck Surgery , Miyagi Cancer Center , Natori-shi , Japan. 11. k Department of Otolaryngology , National Sendai Medical Center , Sendai-shi , Japan. 12. l Department of Otolaryngology , Yamagata University School of Medicine , Yamagata-shi , Japan. 13. m Department of Diagnostic Pathology , Fukushima Medical University School of Medicine , Fukushima , Japan.
Abstract
CONCLUSION: The 3-year progression-free survival rate of non-invasive salivary duct carcinoma (SDC) or adenocarcinoma not otherwise specified (NOS) was significantly better than that of invasive SDC or adenocarcinoma NOS in Carcinoma ex pleomorphic adenoma (CXPA). The presence of invasion is an important prognostic factor for SDC and adenocarcinoma NOS in CXPA. OBJECTIVES: CXPA is a rare parotid gland malignant tumor for which therapy is not yet standardized. The purpose of this study was to review the characteristics of CXPA patients and to analyze their outcomes in the Northern Japan Head and Neck Cancer Society. METHOD: The medical records of 33 patients who had been provided initial treatment in 12 institutes of northern Japan from 2002-2011 were reviewed as a multi-institutional retrospective study. RESULTS: The 3-year overall and progression-free survival rate of all patients was 79.9% and 76.8%, respectively. Both the 3-year overall and progression-free survival rates were 87.5% for patients with non-invasive SDC or adenocarcinoma NOS. The 3-year overall and progression-free survival rates for patients with invasive SDC or adenocarcinoma NOS were 60.4% and 30.5%, respectively. The progression-free survival rates for patients with invasive SDC or adenocarcinoma NOS was significantly poor (p < 0.05).
CONCLUSION: The 3-year progression-free survival rate of non-invasive salivary duct carcinoma (SDC) or adenocarcinoma not otherwise specified (NOS) was significantly better than that of invasive SDC or adenocarcinoma NOS in Carcinoma ex pleomorphic adenoma (CXPA). The presence of invasion is an important prognostic factor for SDC and adenocarcinoma NOS in CXPA. OBJECTIVES:CXPA is a rare parotid gland malignant tumor for which therapy is not yet standardized. The purpose of this study was to review the characteristics of CXPApatients and to analyze their outcomes in the Northern Japan Head and Neck Cancer Society. METHOD: The medical records of 33 patients who had been provided initial treatment in 12 institutes of northern Japan from 2002-2011 were reviewed as a multi-institutional retrospective study. RESULTS: The 3-year overall and progression-free survival rate of all patients was 79.9% and 76.8%, respectively. Both the 3-year overall and progression-free survival rates were 87.5% for patients with non-invasive SDC or adenocarcinoma NOS. The 3-year overall and progression-free survival rates for patients with invasive SDC or adenocarcinoma NOS were 60.4% and 30.5%, respectively. The progression-free survival rates for patients with invasive SDC or adenocarcinoma NOS was significantly poor (p < 0.05).
Entities:
Keywords:
Carcinoma ex pleomorphic adenoma; head and neck cancer; invasion; parotid gland; prognosis
Authors: N Chooback; Y Shen; M Jones; K Kasaian; M Martin; T Ng; T Thomson; M Marra; J Laskin; C Ho Journal: Curr Oncol Date: 2017-06-27 Impact factor: 3.677